Biodesix reports 133% growth in biopharma revenue for Q3
BOULDER — Diagnostics company Biodesix (Nasdaq: BDSX) reported a 133% increase year-over-year in revenue from biopharma services, to $1.4 million from $641,000, and 51% growth in core lung diagnostics revenue, to $4.5 million from $3 million, for the third quarter of 2021.
Overall revenue for the quarter was down 29% year-over-year, to $6.5 million from $9.1 million, but the company attributed that to an expected decline in COVID-19 testing revenue. That was down 91% to $506,000 from $5.5 million.
Biodesix posted a net loss of $11.5 million for the quarter, 30% greater than the $8.8 million it lost in the third quarter of 2020. However, net loss per share declined dramatically, to 41 cents from $31.93.
SPONSORED CONTENT
People Powered: Preparing Longmont Businesses for Economic Success
Longmont Chamber and FNBO present People Powered on April 24, 2024, aiming to inform business owners about workforce development, housing, and transportation issues.
The company ended the quarter with $47.9 million in cash and equivalents on hand. Biodesix stock closed Monday at $7.69 per share, down 1.54% for the day.
© 2021 BizWest Media LLC
BOULDER — Diagnostics company Biodesix (Nasdaq: BDSX) reported a 133% increase year-over-year in revenue from biopharma services, to $1.4 million from $641,000, and 51% growth in core lung diagnostics revenue, to $4.5 million from $3 million, for the third quarter of 2021.
Overall revenue for the quarter was down 29% year-over-year, to $6.5 million from $9.1 million, but the company attributed that to an expected decline in COVID-19 testing revenue. That was down 91% to $506,000 from $5.5 million.
Biodesix posted a net loss of $11.5 million for the quarter, 30% greater than the $8.8 million it lost in the third quarter…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!